Core Viewpoint - Recently, Kefu Medical Technology Co., Ltd. announced plans to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its global strategy and enhance overseas business capabilities [1][2]. Group 1: Company Strategy - Kefu Medical aims to enhance its brand image and international presence through the issuance of H-shares and listing on the Hong Kong Stock Exchange [2][5]. - The company plans to engage with intermediaries to discuss the specifics of the H-share listing, although details are yet to be finalized [2][3]. - The H-share listing is part of a broader strategy to support internationalization, improve capital operation efficiency for cross-border mergers and acquisitions, and strengthen global brand influence [5]. Group 2: Market Environment - The current national policy supports companies going global, making the Hong Kong listing aligned with policy directions and beneficial for international development [5]. - The Hong Kong market is characterized by high internationalization, providing a quality financing platform for companies [5]. Group 3: Overseas Business Development - Kefu Medical is committed to internationalization as a key strategic direction, combining organic growth with external acquisitions to enhance its overseas business layout [5]. - The company has successfully completed acquisitions of Huazhou and Ximaner in the first half of the year, which have effectively supplemented its overseas business resources [5]. Group 4: Technological Integration - Kefu Medical is actively promoting the integration of artificial intelligence (AI) with home medical devices, aiming to enhance the precision and intelligence of products such as dynamic blood glucose meters, blood pressure monitors, fetal heart rate monitors, and hearing aids [6].
可孚医疗宣布拟赴港IPO：搭建H股平台加速推进国际化战略